Colorectal Cancer (CRC) affects the colon and rectum, which are a part of the large intestine. Colorectal cancer occurs when tumours, identified as polyps, develop in the lining of the large intestine. Some of these polyps can become cancerous over time (several years) but some of these polyps may not become malignant at all.
This report provides the current incident population for Colorectal Cancer across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Colorectal Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Colorectal Cancer include:
• Change in bowel habits, including diarrhoea or constipation or a change in the consistency of stools
• Rectal bleeding or blood in the stool
• Persistent abdominal discomfort, such as cramps, gas or pain
• A feeling that the bowel doesn't empty completely
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Colorectal Cancer market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Colorectal Cancer and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Colorectal Cancer incident population.
• Identify sub-populations within Colorectal Cancer which require treatment.
• Gain an understanding of the specific markets that have the largest number of Colorectal Cancer patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line incidence for Colorectal Cancer
• Staging of Colorectal Cancer patients
o Features of Colon Cancer patients
o Features of rectosigmoidal cancer patients
o Features of rectal cancer patients
• Genetic mutations in Colorectal Cancer patients
• Treatment of Colorectal Cancer patients
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Figures
• Progression from polyp to cancer
List of Tables
• American Joint Committee on Cancer (AJCC) TNM Staging for Colorectal Cancer
• Duke’s Staging of Colorectal Cancer
• Colorectal Cancer incidence, total (000s)
• Colorectal Cancer incidence, males (000s)
• Colorectal Cancer incidence, females (000s)
• CRC patients by AJCC Tumour Stage, total (000s)
• CRC patients by site, total (000s)
• Colon cancer patients by AJCC Tumour Stage, total (000s)
• Colon cancer patients by CEA level, total (000s)
• Histopathology of Colon cancer patients, total (000s)
• Rectosigmoidal cancer patients by AJCC Tumour Stage, total (000s)
• Rectosigmoidal cancer patients by CEA level, total (000s)
• Histopathology of Rectal cancer patients, total (000s)
• CRC patients with KRAS mutation, total (000s)
• CRC patients with BRAF mutation, total (000s)
• CRC patients with PIK3CA mutation, total (000s)
• CRC patients with PDL-1 over expression, total (000s)
• CRC patients receiving adjuvant treatment, total (000s)
• CRC patients receiving 1L (metastatic) treatment, total (000s)
• CRC patients receiving 2L treatment, total (000s)
• CRC patients receiving 3L+ treatment, total (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• USA Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Canada Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Canada Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• France Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• France Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Germany Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Germany Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Italy Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Italy Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Spain Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Spain Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• UK Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• UK Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Brazil Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Brazil Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Japan Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Japan Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• India Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• India Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• China Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• China Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Turkey Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Turkey Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Australia Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Australia Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Mexico Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Mexico Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Argentina Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Argentina Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Russia Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Russia Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• Saudi Arabia Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• Saudi Arabia Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
• South Africa Incidence of Colorectal Cancer by 5-yr age cohort, males (000s)
• South Africa Incidence of Colorectal Cancer by 5-yr age cohort, females (000s)
